Matthew Brent Laurens MD
HIV/AIDS Pediatrics, Pediatric Travel and Tropical Medicine, Pediatric Vaccinology and Vaccine Preventable Diseases
Professor of Pediatrics, Tenured, University of Maryland School of Medicine
Join to View Full Profile
22 S Greene StBaltimore, MD 21201
Phone+1 410-706-5328
Fax+1 410-706-1204
Dr. Laurens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Matthew Laurens is a pediatric infectious disease specialist in Baltimore, MD and is affiliated with multiple hospitals in the area, including University of Maryland Medical Center and University of Maryland Upper Chesapeake Medical Center. He received his medical degree from Mercer University School of Medicine and has been in practice 16 years. He specializes in pediatrics, pediatric travel and tropical medicine, and pediatric vaccinology and vaccine preventable diseases and is experienced in pediatric infectious disease.
Education & Training
University of MarylandFellowship, Pediatric Infectious Diseases, 2005 - 2008
Tulane UniversityResidency, Pediatrics, 2001 - 2005
Mercer University School of MedicineClass of 2001
Certifications & Licensure
MD State Medical License 2005 - 2026
LA State Medical License 2002 - 2006
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Infectious Diseases
Clinical Trials
- Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine Start of enrollment: 2019 Jul 08
Publications & Presentations
PubMed
- Advancing typhoid conjugate vaccine implementation in Asia: Regional policy priorities.Alice S Carter, Duncan Steele, Jacob John, Senjuti Saha, Matthew B Laurens
Vaccine. 2025-10-14 - 1 citationsHuman monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adap...Kirsten E Lyke, Andrea A Berry, Matthew B Laurens, Jennifer Winkler, Sudhaunshu Joshi
The Lancet. Infectious Diseases. 2025-09-23 - Vaccine-induced antibodies to a C-terminal Plasmodium falciparum circumsporozoite protein epitope are associated with protection.DeAnna J Friedman-Klabanoff, Travis L Jensen, Casey E Gelber, Richard S Pinapati, John C Tan
The Journal of Infectious Diseases. 2025-08-19
Press Mentions
HMN 2025: How New Monoclonal Antibody Prevents Malaria Infection in Early Clinical TrialOctober 28th, 2025- Extra Spring COVID Boosters Cleared for Some Americans | HealthApril 21st, 2023
- Extra COVID-19 Booster Now Open to Some High-Risk AmericansApril 20th, 2023
- Join now to see all
Grant Support
- Safety, immunogencity, and efficacy of PfSPZ LARC2 malaria vaccine in malaria-exposed adults and childrenUNIVERSITY OF MARYLAND BALTIMORE2024–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
